Delivery Order SPE2DB22D3019-SPE2DB25FK3SJ
- Not listed
- The Defense Logistics Agency (DLA) awarded a $5,155.59 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Imitrex 6 mg/0.5 mL cartridges (0.5 mL units). This firm fixed-price contract represents a non-competitive delivery order with an ultimate completion date of August 11, 2025, and will be performed at the company's corporate office in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,895.22 to AmerisourceBergen Drug Corp for IMITREX 6 mg/0.5 mL cartridges on November 6, 2025, with an ultimate completion date of November 7, 2025. This non-competitive delivery order represents a firm fixed-price transaction issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 and...
- The Defense Logistics Agency awarded a delivery order valued at $14,246.57 to AmerisourceBergen Drug Corp on December 8, 2025, for the supply of Imitrex 6 mg/0.5 ml cartridges. The order is scheduled for completion by December 9, 2025, and utilizes firm fixed pricing with no set-aside designation, indicating the award resulted from open competition. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Imitrex 6 mg/0.5 ml cartridges (0.5 ml) under a firm fixed price contract valued at $1,819.68. The contract carries an ultimate completion date of June 3, 2025, and represents a non-competitive, non-set-aside award. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Imitrex 6 mg/0.5 mL pen injectors with a firm fixed price ceiling value of $1,501.15 and completion date of July 31, 2025. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.9 million through...
- The Defense Logistics Agency awarded a $14,682.33 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Imitrex 6 mg/0.5 mL cartridges (0.5 mL), with an ultimate completion date of August 1, 2025. This non-set-aside contract was competitively awarded on July 31, 2025, and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's broader pharmaceutical supply relationship...
- The Defense Logistics Agency (DLA) awarded a $5,576.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Imitrex 6 mg/0.5 mL pen injectors (0.5 mL units). This contract is not set-aside and represents a competitively awarded delivery order with an ultimate completion date of July 23, 2025. The products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,107.71 to AmerisourceBergen Drug Corp for the supply of Imitrex 6 mg/0.5 mL cartridges on August 18, 2025, with a completion date of August 19, 2025. This firm fixed price delivery order represents a continuation of pharmaceutical supply support to federal medical procurement needs, specifically supporting military and veteran healthcare systems. The award was made through open competition with no set-aside designation,...
- The Defense Logistics Agency awarded a delivery order valued at $12,487.60 to AmerisourceBergen Drug Corp for Imitrex 6 mg/0.5 ml cartridges on July 22, 2025, with completion targeted for July 23, 2025. This firm fixed-price contract represents a non-set-aside award and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Imitrex is a migraine treatment medication, and this delivery order fulfills specific pharmaceutical supply needs for federal healthcare...
- The Defense Logistics Agency awarded a $10,126.17 delivery order to AmerisourceBergen Drug Corp on December 2, 2025, for the supply of Imitrex 6 mg/0.5 mL cartridges. The order, which is a child of AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), represents a firm fixed price purchase utilizing competitive procurement procedures with no set-aside designation. The product will be delivered to AmerisourceBergen's facility in Conshohocken,...
- SPE2DB22D3019Indefinite Delivery Contract
- SPE2DB22D3019-SPE2DB25FK3SJDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,913.45 to AmerisourceBergen Drug Corp for the supply of Imitrex 6 mg/0.5 mL cartridges on May 30, 2025, with an ultimate completion date of June 2, 2025. This firm fixed-price delivery order, which carries no set-aside designation, will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.999 billion prime vehicle designated SPE2DX and running through December 2026 that enables comprehensive pharmaceutical and medical supply support to military healthcare systems worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, has established itself as a critical federal medical procurement vendor through multiple competitively awarded contracts with the DLA Medical Supply Chain. The company's contract portfolio demonstrates extensive experience delivering a broad spectrum of pharmaceutical products across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, and medical devices to support Defense Health Agency and other government healthcare systems. This delivery order for Imitrex, a migraine treatment medication, reflects the company's ongoing role in supplying essential pharmaceuticals to support military personnel and veteran healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.9k | 5/30/25 |